Intelligent Bio Solutions INC

Intelligent Bio Solutions Inc. announced fiscal 2026 results, showcasing 38% year-over-year revenue growth to $4.2 million, driven by a 22% increase in reader installations and a 35% rise in consumable cartridges, alongside a significant expansion in gross profit margin to 48.63%.

Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, a crucial step for its FDA 510(k) submission.

Intelligent Bio Solutions Inc. announced the completion of a Usability Study for its Intelligent Fingerprinting Drug Screening System, a crucial step supporting its FDA 510(k) submission for U.S. market clearance.

Intelligent Bio Solutions Inc. announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System, a crucial step towards FDA 510(k) submission for U.S. market clearance.

Intelligent Bio Solutions Inc. announced an updated total of 3,018,188 outstanding common shares as of July 31, 2026, resulting from recent stock sales, warrant exercises, and advisory agreements.

Intelligent Bio Solutions Inc. announced it has resolved all cybersecurity and software-related review items for its upcoming FDA 510(k) submission, positioning it for a planned U.S. market entry.

Intelligent Bio Solutions Inc. announced its third-quarter fiscal year 2026 results, showcasing a 46% year-over-year revenue increase driven by new customer acquisition and strong re-order rates for consumables.

Intelligent Bio Solutions Inc. reported a significant 47% revenue increase in Q2 2026, driven by new customers and re-orders, alongside a $10 million private placement, despite continued net losses and identified material weaknesses in internal controls.

Intelligent Bio Solutions Inc. reported record quarterly revenue and improved gross profit, but faces substantial doubt about its ability to continue as a going concern and delays in FDA clearance.

Intelligent Bio Solutions reports a decrease in revenue for Q3 2025 but highlights an improved gross profit margin driven by strategic sales mix and operational streamlining.

Intelligent Bio Solutions Inc. announces its financial results for the quarter ended December 31, 2024, alongside key operational achievements including the FDA 510(k) submission and new strategic partnerships.

Intelligent Bio Solutions Inc. saw a revenue increase in the first quarter of 2025, but ongoing research and development costs contributed to a net loss.

Intelligent Bio Solutions Inc. reported increased net losses and a going concern warning for fiscal year 2025, despite progress in FDA submissions and global market expansion for its fingerprint drug screening system.

Intelligent Bio Solutions Inc. files an amendment to its annual report on Form 10-K to update the auditor's consent and clarify document incorporation by reference.

Intelligent Bio Solutions Inc. released its annual 10-K filing, outlining its financial status, operational achievements, and future strategies, including progress on FDA approval and global expansion.

Intelligent Bio Solutions Inc. Director Steven Boyages was granted 5,000 restricted common shares, subject to time-based vesting.

Intelligent Bio Solutions Inc. director Nicola Fraser was granted 5,000 restricted common shares, subject to a 12-month vesting period.

Intelligent Bio Solutions CFO Spiro Sakiris received 30,500 restricted common stock shares under the 2019 Long Term Incentive Plan, subject to vesting conditions.

Intelligent Bio Solutions Inc. director Jonathan Scott Hurd was granted 5,000 restricted shares of common stock, subject to a 12-month vesting period.

Intelligent Bio Solutions Inc. director Jason Isenberg was granted 5,000 restricted common shares, subject to a 12-month vesting period.

Intelligent Bio Solutions Inc. CEO Harry Simeonidis received 30,500 restricted common shares under the company's 2019 Long Term Incentive Plan, subject to vesting conditions.

Intelligent Bio Solutions Inc. will hold its Annual Meeting on October 16, 2025, seeking stockholder approval for director elections, auditor ratification, an increase in its long-term incentive plan shares, the issuance of shares from a warrant exercise inducement, and a potential reverse stock split.

Intelligent Bio Solutions Inc. files a supplement to its proxy statement to include Inline XBRL tagging of disclosures related to insider trading and equity award policies.

Intelligent Bio Solutions Inc. is amending its 2019 Long Term Incentive Plan to reduce the number of shares to be added, following a recommendation against the original proposal from proxy advisory firm Glass, Lewis & Co. and feedback from stockholders.

Intelligent Bio Solutions Inc. is soliciting proxies for its Annual Meeting of Stockholders to be held on May 8, 2025, including a proposal to amend its 2019 Long Term Incentive Plan.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 141,397 shares, representing 5.91% of Intelligent Bio Solutions Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported a 9.99% stake in Intelligent Bio Solutions Inc., holding 163,571 shares.

Alyeska Investment Group, L.P. and its affiliates have reported a 9.99% beneficial ownership stake in Intelligent Bio Solutions Inc. as of September 30, 2025.

Bigger Capital Fund L.P., District 2 Capital Fund L.P., and related entities, including Michael Bigger, have filed an amended Schedule 13G, disclosing their passive beneficial ownership in Intelligent Bio Solutions Inc., with holdings capped by a 4.99% beneficial ownership limitation on exercisable warrants.